Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?

Ernesto Rossi, Giovanni Schinzari, Ilaria Grazia Zizzari, Brigida Anna Maiorano, Monica Maria Pagliara, Maria Grazia Sammarco, Vincenzo Fiorentino, Gianluigi Petrone, Alessandra Cassano, Guido Rindi, Emilio Bria, Maria Antonietta Blasi, Marianna Nuti, Giampaolo Tortora

Research output: Contribution to journalReview article

Abstract

No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors. Unfortunately, only a minority of patients obtain a clinical benefit with immunotherapy. The immunological features of mUM were reviewed in order to understand if immunotherapy could still play a role for this disease.

Original languageEnglish
JournalCancers
Volume11
Issue number8
DOIs
Publication statusPublished - Jul 26 2019

    Fingerprint

Cite this

Rossi, E., Schinzari, G., Zizzari, I. G., Maiorano, B. A., Pagliara, M. M., Sammarco, M. G., Fiorentino, V., Petrone, G., Cassano, A., Rindi, G., Bria, E., Blasi, M. A., Nuti, M., & Tortora, G. (2019). Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy? Cancers, 11(8). https://doi.org/10.3390/cancers11081055